Sarcoidosis during infliximab therapy for Crohn’s disease

Tumor necrosis factor‐α (TNF‐α) antagonists are effective for inflammatory diseases, such as Crohn’s disease, rheumatoid arthritis (RA) and psoriasis. Although TNF‐α antagonists are also useful for sarcoidosis, paradoxical occurrence of sarcoidosis or sarcoidal reaction may be observed. We report a Crohn’s disease patient, who developed sarcoidosis during infliximab therapy. A 35‐year‐old man had been receiving infliximab for 7 months for Crohn’s disease. He developed cough and fever, accompanied by an infiltrated erythematous plaque on his right knee. The chest radiography, skin biopsy and laboratory findings were all consistent with sarcoidosis.

[1]  J. Hampe,et al.  Genome-wide association analysis in sarcoidosis and Crohn's disease unravels a common susceptibility locus on 10p12.2. , 2008, Gastroenterology.

[2]  D. Wendling,et al.  Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. , 2008, Clinical and experimental rheumatology.

[3]  A. Ishida-Yamamoto,et al.  Psoriasiform and pustular eruption induced by infliximab , 2007, The Journal of dermatology.

[4]  R. Westhovens,et al.  Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients , 2007, Clinical Rheumatology.

[5]  R. Inman,et al.  Pulmonary sarcoidosis developing during infliximab therapy. , 2006, Arthritis and rheumatism.

[6]  E. Pertuiset,et al.  Granulomatous tattoo reaction in a patient treated with etanercept , 2006, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  V. Rodríguez-Valverde,et al.  Development of sarcoidosis during etanercept therapy. , 2006, Arthritis and rheumatism.

[8]  M. Weinblatt,et al.  Granulomatous lung disease occurring during etanercept treatment. , 2005, Arthritis and rheumatism.

[9]  S. Ehlers,et al.  Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. , 2005, Seminars in arthritis and rheumatism.

[10]  K. Hobbs.  Chronic sarcoid arthritis treated with intraarticular etanercept. , 2005, Arthritis and rheumatism.

[11]  J. Mazur,et al.  Treatment of sarcoidosis with infliximab. , 2005, Chest.

[12]  B. Haraoui.  Differentiating the efficacy of tumor necrosis factor inhibitors. , 2005, The Journal of rheumatology. Supplement.

[13]  E. Keystone,et al.  The utility of tumour necrosis factor blockade in orphan diseases , 2004, Annals of the rheumatic diseases.

[14]  D. Khanna,et al.  Etanercept ameliorates sarcoidosis arthritis and skin disease. , 2003, The Journal of rheumatology.

[15]  D. Schroeder,et al.  Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. , 2003, Chest.

[16]  R. Speich,et al.  Pulmonary granulomas after tumour necrosis factor alpha antagonist therapy , 2003, Thorax.

[17]  M. Ziegenhagen,et al.  The cytokine network in sarcoidosis and its clinical relevance , 2003, Journal of internal medicine.

[18]  S. Brantley,et al.  Lung injury linked to etanercept therapy. , 2002, Chest.

[19]  D. O'Donoghue,et al.  Crohn's colitis and sarcoidosis. , 1986, Postgraduate medical journal.

[20]  K. Kurashima,et al.  Development of sarcoidosis during etanercept therapy. , 2008, Internal medicine.

[21]  P. Zarco,et al.  Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. , 2007, Clinical and experimental rheumatology.